Skip to main content
Year archive

BerGenBio — 2021 filings

All 175 regulatory filings released by BerGenBio (BGBIO) in 2021, sourced directly from the official regulator.

175 Filings
2021 Period
2021 filings (175)
Filing Released Lang
Financial calendar
Report Publication Announcement
2021-12-17 English
BerGenBio ASA: Notice of Extraordinary General Meeting
AGM Information
2021-12-16 Norwegian
BerGenBio ASA: Notice of Extraordinary General Meeting
AGM Information
2021-12-16 Norwegian
BerGenBio ASA: Notice of Extraordinary General Meeting
AGM Information
2021-12-16 Norwegian
BerGenBio ASA: Notice of Extraordinary General Meeting
AGM Information
2021-12-16 English
BerGenBio announces exclusive in-license of key intellectual property rights from UT Southwestern Medical Center
M&A Activity
2021-12-16 English
BerGenBio announces exclusive in-license of key intellectual property rights from UT Southwestern Medical Center
Regulatory Filings
2021-12-16 English
BerGenBio to present at DNB Nordic Healthcare Conference 2021
Report Publication Announcement
2021-12-14 English
BerGenBio to present at DNB Nordic Healthcare Conference 2021
Regulatory Filings
2021-12-14 English
BERGENBIO PRESENTS UPDATED BEMCENTINIB AML DATA AT ASH 2021 MEETING
Earnings Release FY 2021
2021-12-13 English
BERGENBIO PRESENTS UPDATED BEMCENTINIB AML DATA AT ASH 2021 MEETING
Earnings Release FY 2021
2021-12-13 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2021-11-17 Norwegian
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2021-11-17 English
BERGENBIO ASA: RESULTS FOR THE THIRD QUARTER OF 2021
Interim / Quarterly Report Q3 2021
2021-11-16 English
BERGENBIO ASA: RESULTS FOR THE THIRD QUARTER OF 2021
Earnings Release Q3 2021
2021-11-16 English
BERGENBIO ASA: RESULTS FOR THE THIRD QUARTER OF 2021
Earnings Release Q3 2021
2021-11-16 English
BerGenBio ASA: Increase of share capital, exercise of share options
Share Issue/Capital Change
2021-11-09 English
BerGenBio ASA: Increase of share capital, exercise of share options
Share Issue/Capital Change
2021-11-09 English
BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB IN STK11-MUTATED ADVANCED/METASTATIC NON-SMALL LUNG CANCER (NSCLC)
Regulatory Filings
2021-11-09 English
BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB IN STK11-MUTATED ADVANCED/METASTATIC NON-SMALL LUNG CANCER (NSCLC)
Regulatory Filings
2021-11-09 English
BERGENBIO PRESENTS PRE-CLINICAL AND CLINICAL DATA ON BEMCENTINIB IN STK11-POSITIVE NSCLC AT SITC ANNUAL MEETING 2021
Regulatory Filings
2021-11-09 English
BERGENBIO PRESENTS PRE-CLINICAL AND CLINICAL DATA ON BEMCENTINIB IN STK11-POSITIVE NSCLC AT SITC ANNUAL MEETING 2021
Regulatory Filings
2021-11-09 English
BERGENBIO TO PRESENT UPDATED BEMCENTINIB AML DATA AT ASH 2021 MEETING
Regulatory Filings
2021-11-04 English
BERGENBIO TO PRESENT UPDATED BEMCENTINIB AML DATA AT ASH 2021 MEETING
Regulatory Filings
2021-11-04 English
BERGENBIO ASA: INVITATION TO THIRD QUARTER 2021 RESULTS PRESENTATION AND WEBCAST
Report Publication Announcement
2021-11-04 Norwegian
BERGENBIO ASA: INVITATION TO THIRD QUARTER 2021 RESULTS PRESENTATION AND WEBCAST
Report Publication Announcement
2021-11-04 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2021-10-04 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2021-10-04 English
BERGENBIO ANNOUNCES POSTER PRESENTATION AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2021
Regulatory Filings
2021-10-01 English
BERGENBIO ANNOUNCES POSTER PRESENTATION AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2021
Regulatory Filings
2021-10-01 English
BerGenBio ASA: Increase of share capital, exercise of share options
Share Issue/Capital Change
2021-09-30 Norwegian
BerGenBio ASA: Increase of share capital, exercise of share options
Share Issue/Capital Change
2021-09-30 Norwegian
BERGENBIO COMPLETES RECRUITMENT OF PHASE II AML STUDY (BGBC003)
Regulatory Filings
2021-09-07 English
BERGENBIO COMPLETES RECRUITMENT OF PHASE II AML STUDY (BGBC003)
Regulatory Filings
2021-09-07 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2021-09-06 Norwegian
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2021-09-06 English
BerGenBio ASA: Increase of share capital, exercise of share options
Share Issue/Capital Change
2021-08-31 Norwegian
BerGenBio ASA: Increase of share capital, exercise of share options
Share Issue/Capital Change
2021-08-31 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2021-08-26 Norwegian
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2021-08-26 English
BerGenBio ASA: Increase of share capital, exercise of share options
Share Issue/Capital Change
2021-08-23 English
BerGenBio ASA: Increase of share capital, exercise of share options
Share Issue/Capital Change
2021-08-23 English
BERGENBIO ASA: LEADERSHIP CHANGE
Board/Management Information
2021-08-22 English
BERGENBIO ASA: LEDERSKIFTE
Board/Management Information
2021-08-22 Norwegian
BERGENBIO ASA: LEADERSHIP CHANGE
Board/Management Information
2021-08-22 English
BERGENBIO ASA: LEDERSKIFTE
Board/Management Information
2021-08-22 Norwegian
BERGENBIO ASA: RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2021
Earnings Release Q2 2021
2021-08-17 English
BERGENBIO ASA: RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2021
Interim / Quarterly Report H1 2021
2021-08-17 English
BERGENBIO ASA: RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2021
Report Publication Announcement H1 2021
2021-08-17 English
BERGENBIO ANNOUNCES CHANGES TO SENIOR MANAGEMENT
Board/Management Information
2021-08-06 English
BERGENBIO ANNOUNCES CHANGES TO SENIOR MANAGEMENT
Board/Management Information
2021-08-06 English
BERGENBIO ASA: INVITATION TO PRESENTATION OF SECOND QUARTER AND HALF YEAR 2021 RESULTS
Report Publication Announcement
2021-08-04 Norwegian
BERGENBIO ASA: INVITATION TO PRESENTATION OF SECOND QUARTER AND HALF YEAR 2021 RESULTS
Report Publication Announcement
2021-08-04 Norwegian
BERGENBIO COVID-19 DATA PRESENTED AT THE ANNUAL AMERICAN SOCIETY FOR VIROLOGY
Regulatory Filings
2021-07-21 English
BERGENBIO COVID-19 DATA PRESENTED AT THE ANNUAL AMERICAN SOCIETY FOR VIROLOGY
Regulatory Filings
2021-07-21 English
BERGENBIO PRESENTS ENCOURAGING COMBINED DATA FOR BEMCENTINIB FROM TWO PHASE II COVID-19 STUDIES AT ECCMID
Regulatory Filings
2021-07-12 English
BERGENBIO PRESENTS ENCOURAGING COMBINED DATA FOR BEMCENTINIB FROM TWO PHASE II COVID-19 STUDIES AT ECCMID
Earnings Release Q2 2021
2021-07-12 English
PRECLINICAL BEMCENTINIB AND TILVESTAMAB DATA PRESENTED AT EAU 2021
Regulatory Filings
2021-07-10 English
PRECLINICAL BEMCENTINIB AND TILVESTAMAB DATA PRESENTED AT EAU 2021
Regulatory Filings
2021-07-10 English
BERGENBIO PRESENTING COVID-19 DATA IN LATE-BREAKING ABSTRACT PRESENTATION AT ECCMID 2021
Environmental & Social Information
2021-06-29 English
BERGENBIO PRESENTING COVID-19 DATA IN LATE-BREAKING ABSTRACT PRESENTATION AT ECCMID 2021
Regulatory Filings
2021-06-29 English
BERGENBIO TO PRESENT AT 4th ANNUAL NEXT GEN IMMUNO-ONCOLOGY VIRTUAL CONGRESS
Regulatory Filings
2021-06-28 English
BERGENBIO TO PRESENT AT 4th ANNUAL NEXT GEN IMMUNO-ONCOLOGY VIRTUAL CONGRESS
Regulatory Filings
2021-06-28 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2021-06-16 Norwegian
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2021-06-16 Norwegian
BerGenBio ASA: Increase of share capital, exercise of share options and disclosure of trade by primary insider
Share Issue/Capital Change
2021-06-11 English
BerGenBio ASA: Increase of share capital, exercise of share options and disclosure of trade by primary insider
Director's Dealing
2021-06-11 English
BerGenBio ASA: Increase of share capital, exercise of share options and disclosure of trade by primary insider
Share Issue/Capital Change
2021-06-11 English
BERGENBIO PRESENTS ENCOURAGING UPDATED PRELIMINARY DATA FROM PHASE II STUDY IN RELAPSED AML PATIENTS AT EHA VIRTUAL MEETING
Regulatory Filings
2021-06-11 English
BERGENBIO PRESENTERER LOVENDE OPPDATERTE PRELIMINÆRE DATA FRA FASE-II STUDIE I AML PASIENTER MED TILBAKEFALL PÅ VIRTUELT EHA SEMINAR
Earnings Release Q2 2021
2021-06-11 Norwegian
BERGENBIO PRESENTS ENCOURAGING UPDATED PRELIMINARY DATA FROM PHASE II STUDY IN RELAPSED AML PATIENTS AT EHA VIRTUAL MEETING
Investor Presentation
2021-06-11 English
BERGENBIO PRESENTERER LOVENDE OPPDATERTE PRELIMINÆRE DATA FRA FASE-II STUDIE I AML PASIENTER MED TILBAKEFALL PÅ VIRTUELT EHA SEMINAR
Earnings Release Q2 2021
2021-06-11 Norwegian
BERGENBIO ANNOUNCES LATE-BREAKING ABSTRACT PRESENTATION AT ECCMID 2021
Regulatory Filings
2021-06-10 English
BERGENBIO ANNOUNCES LATE-BREAKING ABSTRACT PRESENTATION AT ECCMID 2021
Regulatory Filings
2021-06-10 English
BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB / ANTI-PD-(L)1 COMBINATION IN NSCLC
Regulatory Filings
2021-06-08 English
BERGENBIO MOTTAR FDA FAST TRACK DESIGNATION FOR BEMCENTINIB/ANTI-PD-(L)1 KOMBINASJON I NSCLC
Regulatory Filings
2021-06-08 Norwegian
BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB / ANTI-PD-(L)1 COMBINATION IN NSCLC
Regulatory Filings
2021-06-08 English
BERGENBIO MOTTAR FDA FAST TRACK DESIGNATION FOR BEMCENTINIB/ANTI-PD-(L)1 KOMBINASJON I NSCLC
Regulatory Filings
2021-06-08 Norwegian
BERGENBIO TO PRESENT PRECLINICAL DATA ON TILVESTAMAB IN CHRONIC KIDNEY DISEASE AT ERA-EDTA VIRTUAL CONGRESS 2021
Environmental & Social Information
2021-06-07 English
BERGENBIO TO PRESENT PRECLINICAL DATA ON TILVESTAMAB IN CHRONIC KIDNEY DISEASE AT ERA-EDTA VIRTUAL CONGRESS 2021
Regulatory Filings
2021-06-07 English
BERGENBIO PRESENTS DATA FROM PHASE I/II BEMCENTINIB/ERLOTINIB COMBINATION TRIAL IN NSCLC AT ASCO MEETING
Earnings Release FY 2021
2021-06-04 English
BERGENBIO PRESENTS DATA FROM PHASE I/II BEMCENTINIB/ERLOTINIB COMBINATION TRIAL IN NSCLC AT ASCO MEETING
Regulatory Filings
2021-06-04 English
BERGENBIO TO PRESENT AT ABGSC SEMINAR
Regulatory Filings
2021-05-25 English
BERGENBIO TO PRESENT AT ABGSC SEMINAR
Report Publication Announcement
2021-05-25 English
BERGENBIO TO PRESENT DATA FROM PHASE I/II BEMCENTINIB/ERLOTINIB COMBINATION TRIAL IN NSCLC AT ASCO MEETING
Regulatory Filings
2021-05-20 English
BERGENBIO TO PRESENT DATA FROM PHASE I/II BEMCENTINIB/ERLOTINIB COMBINATION TRIAL IN NSCLC AT ASCO MEETING
Regulatory Filings
2021-05-20 English
BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2021
Interim / Quarterly Report Q1 2021
2021-05-19 English
BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2021
Interim / Quarterly Report Q1 2021
2021-05-19 English
BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2021
Earnings Release Q1 2021
2021-05-19 English
BERGENBIO PRESENTING AT SACHS 7[th] ANNUAL IMMUNO-ONCOLOGY INNOVATION FORUM
Regulatory Filings
2021-05-18 English
BERGENBIO PRESENTING AT SACHS 7[th] ANNUAL IMMUNO-ONCOLOGY INNOVATION FORUM
Report Publication Announcement
2021-05-18 English
BERGENBIO KUNNGJØR TOPPLINJEDATA FRA FASE-II UTPRØVINGSSTUDIE AV BEMCENTINIB I SYKEHUSINNLAGTE COVID-19 PASIENTER
Earnings Release Q2 2021
2021-05-18 Norwegian
BERGENBIO ANNOUNCES TOP LINE DATA FROM PHASE II TRIAL ASSESSING BEMCENTINIB IN HOSPITALISED COVID-19 PATIENTS
Regulatory Filings
2021-05-18 English
BERGENBIO KUNNGJØR TOPPLINJEDATA FRA FASE-II UTPRØVINGSSTUDIE AV BEMCENTINIB I SYKEHUSINNLAGTE COVID-19 PASIENTER
Regulatory Filings
2021-05-18 Norwegian
BERGENBIO ANNOUNCES TOP LINE DATA FROM PHASE II TRIAL ASSESSING BEMCENTINIB IN HOSPITALISED COVID-19 PATIENTS
Earnings Release Q2 2021
2021-05-18 English
BERGENBIO TO PRESENT UPDATED CLINICAL DATA AT EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2021 VIRTUAL MEETING
Regulatory Filings
2021-05-12 English
BERGENBIO TO PRESENT UPDATED CLINICAL DATA AT EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2021 VIRTUAL MEETING
Regulatory Filings
2021-05-12 English
BEMCENTINIB PRE-CLINICAL COVID-19 DATA PRESENTED AT VIRTUAL IMMUNOLOGY 2021
Regulatory Filings
2021-05-11 English
BEMCENTINIB PRE-CLINICAL COVID-19 DATA PRESENTED AT VIRTUAL IMMUNOLOGY 2021
Regulatory Filings
2021-05-11 English
BerGenBio ASA: Grant of share options
Director's Dealing
2021-05-07 English
BerGenBio ASA: Grant of share options
Director's Dealing
2021-05-07 English
BerGenBio ASA: Grant of share options
Remuneration Information
2021-05-07 English
BERGENBIO ASA: INVITATION TO PRESENTATION OF FIRST QUARTER 2021 RESULTS
Report Publication Announcement
2021-05-05 Norwegian
BERGENBIO ASA: INVITATION TO PRESENTATION OF FIRST QUARTER 2021 RESULTS
Report Publication Announcement
2021-05-05 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2021-04-30 Norwegian
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2021-04-30 English
BERGENBIO TO PRESENT AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
Regulatory Filings
2021-04-28 English
BERGENBIO TO PRESENT AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
Regulatory Filings
2021-04-28 English
BEMCENTINIB PRE-CLINICAL COVID-19 DATA TO BE PRESENTED AT VIRUTAL IMMUNOLOGY 2021
Regulatory Filings
2021-04-26 English
BEMCENTINIB PRE-CLINICAL COVID-19 DATA TO BE PRESENTED AT VIRUTAL IMMUNOLOGY 2021
Regulatory Filings
2021-04-26 English
BerGenBio ASA: Increase of share capital, exercise of share options
Share Issue/Capital Change
2021-04-23 Norwegian
BerGenBio ASA: Increase of share capital, exercise of share options
Share Issue/Capital Change
2021-04-23 English
BERGENBIO PRESENTING AT ARCTIC SECURITIES BIOTECH WEBINAR
Report Publication Announcement
2021-04-21 English
BERGENBIO PRESENTING AT ARCTIC SECURITIES BIOTECH WEBINAR
Report Publication Announcement
2021-04-21 English
BERGENBIO KUNNGJØR OPPDATERING FRA FASE-II UTPRØVINGSSTUDIER AV BEMCENTINIB I SYKEHUSINNLAGTE COVID-19 PASIENTER
Earnings Release Q2 2021
2021-04-19 Norwegian
BERGENBIO ANNOUNCES UPDATE FROM INVESTIGATIONAL PHASE II TRIALS ASSESSING BEMCENTINIB IN HOSPITALISED COVID-19 PATIENTS
Regulatory Filings
2021-04-19 English
BERGENBIO KUNNGJØR OPPDATERING FRA FASE-II UTPRØVINGSSTUDIER AV BEMCENTINIB I SYKEHUSINNLAGTE COVID-19 PASIENTER
Regulatory Filings
2021-04-19 Norwegian
BERGENBIO ANNOUNCES UPDATE FROM INVESTIGATIONAL PHASE II TRIALS ASSESSING BEMCENTINIB IN HOSPITALISED COVID-19 PATIENTS
Regulatory Filings
2021-04-19 English
Flagging
Major Shareholding Notification
2021-03-31 Swedish
BERGENBIO ANNOUNCES STOPPED RECRUITMENT TO THE BEMCENTINIB ARM IN UK ACCORD COVID PLATFORM TRIAL
Investor Presentation
2021-03-30 English
BERGENBIO ANNOUNCES STOPPED RECRUITMENT TO THE BEMCENTINIB ARM IN UK ACCORD COVID PLATFORM TRIAL
Regulatory Filings
2021-03-30 English
BERGENBIO ASA: MINUTES FROM THE ANNUAL GENERAL MEETING
AGM Information
2021-03-19 Norwegian
BERGENBIO ASA: MINUTES FROM THE ANNUAL GENERAL MEETING
AGM Information
2021-03-19 Norwegian
BERGENBIO ASA: MINUTES FROM THE ANNUAL GENERAL MEETING
AGM Information
2021-03-19 English
BERGENBIO ASA: DISCLOSURE OF LARGE SHAREHOLDINGS-PROXIES RECEIVED IN CONNECTION WITH THE AGM 19TH MARCH 2021
Declaration of Voting Results & Voting Rights Announcements
2021-03-15 English
BERGENBIO ASA: DISCLOSURE OF LARGE SHAREHOLDINGS-PROXIES RECEIVED IN CONNECTION WITH THE AGM 19TH MARCH 2021
AGM Information
2021-03-15 English
BERGENBIO COMPLETES ENROLMENT INTO LATEST COHORT OF PHASE II BEMCENTINIB COMBINATION STUDY IN REFRACTORY NSCLC
Regulatory Filings
2021-03-12 English
BERGENBIO COMPLETES ENROLMENT INTO LATEST COHORT OF PHASE II BEMCENTINIB COMBINATION STUDY IN REFRACTORY NSCLC
Regulatory Filings
2021-03-12 English
BERGENBIO TO PRESENT AT UPCOMING INVESTOR CONFERENCES
Report Publication Announcement
2021-03-08 English
BERGENBIO TO PRESENT AT UPCOMING INVESTOR CONFERENCES
Regulatory Filings
2021-03-08 English
BERGENBIO PRESENTS PRECLINICAL COVID-19 DATA AT ANNUAL CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI 2021)
Regulatory Filings
2021-03-06 English
BERGENBIO PRESENTS PRECLINICAL COVID-19 DATA AT ANNUAL CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI 2021)
Regulatory Filings
2021-03-06 English
BERGENBIO PRESENTS PRECLINICAL COVID-19 DATA AT ANNUAL CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI 2021)
Regulatory Filings
2021-03-06 English
BERGENBIO PRESENTS PRECLINICAL COVID-19 DATA AT ANNUAL CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI 2021)
Regulatory Filings
2021-03-06 English
BERGENBIO ANNOUNCES START OF PHASE 1B TRIAL OF ANTI-AXL ANTIBODY TILVESTAMAB (BGB149)
Regulatory Filings
2021-03-05 English
BERGENBIO ANNOUNCES START OF PHASE 1B TRIAL OF ANTI-AXL ANTIBODY TILVESTAMAB (BGB149)
Regulatory Filings
2021-03-05 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2021-03-04 Norwegian
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2021-03-04 English
BERGENBIO CLOSES RECRUITMENT INTO TRIAL ASSESSING BEMCENTINIB IN COVID-19 PATIENTS
Regulatory Filings
2021-03-04 English
BERGENBIO CLOSES RECRUITMENT INTO TRIAL ASSESSING BEMCENTINIB IN COVID-19 PATIENTS
Regulatory Filings
2021-03-04 English
BerGenBio ASA: Increase of share capital, exercise of share options
Share Issue/Capital Change
2021-03-02 Norwegian
BerGenBio ASA: Increase of share capital, exercise of share options
Share Issue/Capital Change
2021-03-02 English
BERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2021-02-25 English
BERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2021-02-25 English
BERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2021-02-25 Norwegian
BERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2021-02-25 English
BERGENBIO ASA: ANNUAL REPORT 2020
Report Publication Announcement
2021-02-25 Norwegian
BERGENBIO ASA: ANNUAL REPORT 2020
Annual Report FY 2020
2021-02-25 Norwegian
BERGENBIO ASA: ANNUAL REPORT 2020
Report Publication Announcement
2021-02-25 Norwegian
BERGENBIO ASA: Board approval of 2020 annual financial statement
Report Publication Announcement
2021-02-23 English
BERGENBIO ASA: Board approval of 2020 annual financial statement
Report Publication Announcement
2021-02-23 English
BerGenBio ASA: Primary Insider notification
Director's Dealing
2021-02-23 English
BERGENBIO TO PRESENT PRECLINICAL COVID-19 DATA AT THE CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI 2021)
Regulatory Filings
2021-02-17 English
BERGENBIO TO PRESENT PRECLINICAL COVID-19 DATA AT THE CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI 2021)
Environmental & Social Information
2021-02-17 English
BerGenBio ASA: Primary Insider notification
Director's Dealing
2021-02-11 English
BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2020
Earnings Release Q4 2020
2021-02-10 English
BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2020
Interim / Quarterly Report Q4 2020
2021-02-10 English
BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2020
Earnings Release Q4 2020
2021-02-10 English
SECOND DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF BERGENBIO'S BGBC020 TRIAL ASSESSING BEMCENTINIB IN COVID-19 PATIENTS
Regulatory Filings
2021-02-08 English
SECOND DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF BERGENBIO'S BGBC020 TRIAL ASSESSING BEMCENTINIB IN COVID-19 PATIENTS
Regulatory Filings
2021-02-08 English
BERGENBIO PRESENTS UPDATES FROM ONGOING PHASE II BEMCENTINIB COMBINATION STUDY IN REFRACTORY NSCLC AT WCLC 2020
Investor Presentation
2021-01-29 English
BerGenBio presenterer oppdateringer fra den pågående fase-II bemcentinib kombinasjonsstudien i ikke-småcellet lungekreft (NSCLC) på WCLC 2020
Earnings Release Q1 2021
2021-01-29 Norwegian
BERGENBIO PRESENTS UPDATES FROM ONGOING PHASE II BEMCENTINIB COMBINATION STUDY IN REFRACTORY NSCLC AT WCLC 2020
Regulatory Filings
2021-01-29 English
BerGenBio presenterer oppdateringer fra den pågående fase-II bemcentinib kombinasjonsstudien i ikke-småcellet lungekreft (NSCLC) på WCLC 2020
Investor Presentation
2021-01-29 Norwegian
BerGenBio ASA: Primary Insider notification
Major Shareholding Notification
2021-01-28 English
BERGENBIO ASA: INVITATION TO FOURTH QUARTER 2020 RESULTS
Report Publication Announcement
2021-01-27 Norwegian
BERGENBIO ASA: INVITATION TO FOURTH QUARTER 2020 RESULTS
Report Publication Announcement
2021-01-27 English
BERGENBIO PRESENTERER OPPDATERINGER FRA DEN PÅGÅENDE FASE-II BEMCENTINIB KOMBINASJONSSTUDIEN I IKKE-SMÅCELLET LUNGEKREFT (NSCLC) PÅ WCLC 2020
Report Publication Announcement
2021-01-13 Norwegian
BERGENBIO PRESENTERER OPPDATERINGER FRA DEN PÅGÅENDE FASE-II BEMCENTINIB KOMBINASJONSSTUDIEN I IKKE-SMÅCELLET LUNGEKREFT (NSCLC) PÅ WCLC 2020
Regulatory Filings
2021-01-13 Norwegian
BERGENBIO TO PRESENT UPDATES FROM ONGOING PHASE II BEMCENTINIB COMBINATION STUDY IN REFRACTORY NSCLC AT WCLC 2020
Regulatory Filings
2021-01-13 English
BERGENBIO TO PRESENT UPDATES FROM ONGOING PHASE II BEMCENTINIB COMBINATION STUDY IN REFRACTORY NSCLC AT WCLC 2020
Earnings Release FY 2020
2021-01-13 English
BERGENBIO PRESENTING AT VIRTUAL INVESTOR CONFERENCES
Investor Presentation
2021-01-12 English
BERGENBIO PRESENTING AT VIRTUAL INVESTOR CONFERENCES
Report Publication Announcement
2021-01-12 English
DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF BERGENBIO'S BGBC020 TRIAL ASSESSING BEMCENTINIB IN COVID-19 PATIENTS
Regulatory Filings
2021-01-11 English
DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF BERGENBIO'S BGBC020 TRIAL ASSESSING BEMCENTINIB IN COVID-19 PATIENTS
Regulatory Filings
2021-01-11 English